AzTrials
AzTrials

Postoperative PainNCT04643132

S-ketamine Prevents Postoperative Pain and Cognitive Dysfunction After Tibial Fracture

A study testing Normal saline, S-ketamine (low-dose) and S-ketamine (high-dose) in people with Postoperative Pain and Postoperative Cognitive Dysfunction, run by Tianjin Medical University General Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Purpose: To explore effects of S-ketamine on postoperative pain and cognitive dysfunction after tibial fracture and orthopedic surgery. To evaluate and examine the incidence of adverse effects with the purpose of selecting the optimum dose. Read more about this study

Who is it for?
Ages 65 to 85 years
What is being tested?
Normal saline, S-ketamine (low-dose) and S-ketamine (high-dose)
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
120 participants
Where
1 siteChina
Study dates
15 Dec 2020to 15 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 to 85 years
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Subject is scheduled to undergo tibial fracture with orthopedic surgery under a short general anesthesia of less than 2 hours
  • Subject's American Society of Anesthesiologists physical status is I-II.
  • The subject's parent/legally authorized guardian has given written informed consent to participate.

Who cannot join

  • Subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure.
  • Subject has a diagnosis of Insulin dependent diabetes.
  • Subject is allergy and contraindication to S-ketamine.
  • Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids.
  • Subject has any contraindication for the use of patient-controlled analgesia (PCA).
  • Subject is pregnant or breast-feeding.
  • Subject is obese (body mass index >30kg/m^2).
  • Subject is incapacity to comprehend pain assessment and cognitive assessment.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Tianjin Medical University General Hospital

    Tianjin, 300052

    Guolin Wang, +8615822855556, wangguolinghad@hotmail.com

    Recruiting

Other trials in China

About this study

Official title: S-ketamine Prevents Tibial Fracture-associated Postoperative Pain and Cognitive Dysfunction After Orthopedic Surgery in Patients: a Randomized Double-blind Controlled Trial

Purpose:

To explore effects of S-ketamine on postoperative pain and cognitive dysfunction after tibial fracture and orthopedic surgery.

To evaluate and examine the incidence of adverse effects with the purpose of selecting the optimum dose.

Read the detailed description

With the increase in human life span, orthopedic injuries and subsequent repair surgery have become a major health problem which impairs the life quality of patients and burdens healthcare systems worldwide. Poor post-surgical pain control is a leading factor that hinders the physical rehabilitation and musculoskeletal functional recovery, and causes acute cognitive impairment and chronic pain syndrome. Also, existing treatments of opioids and non-steroidal anti-inflammatory drugs have potential drawbacks, which may in turn interfere with bone healing. Therefore, prophylaxis of fracture-associated pain is indispensable to postoperative comfort and satisfaction.

There is no denying the fact that pathologic pain is related to central glutaminergic system and N-methyl-d-aspartate (NMDA) receptor activation induced central sensitization. Also, we previously reported that neuroinflammation is associated with pain development and cognitive dysfunction. Ketamine, a NMDA receptor antagonist, is effective in reversing NMDA receptor activation underlying pain states. But the side effects of ketamine limit its clinical application, such as Delirium, gibberish and agitation. It is clarified that S-ketamine has lower side effects than ketamine and that antinociception of S-ketamine is stronger than ketamine. The following study is carried out to evaluate whether S-ketamine can prevent postoperative pain and cognitive impairment after tibial fracture and orthopedic surgery in patients.

Being tested
Normal saline, S-ketamine (low-dose), S-ketamine (high-dose)
Keywords
S-ketamine, tibial fracture, orthopedic surgery, pain intensity
Medical subject headings
Pain, Postoperative, Postoperative Cognitive Complications, Tibial Fractures, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Normal salineDrug

    Also called 0. 9% Sodium Chloride Injection

    After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.

  • S-ketamine (low-dose)Drug

    Also called Esketamine Hydrochloride Injection

    After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.

  • S-ketamine (high-dose)Drug

    Also called Esketamine Hydrochloride Injection

    After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.

Study groups in NCT04643132
Study groupRoleWhat they receive
Normal saline in patientsPlacebo comparatorAfter the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
Receives: Drug: Normal saline
S-ketamine at low dose in patientsActive comparatorAfter the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
Receives: Drug: S-ketamine (low-dose)
S-ketamine at high dose in patientsActive comparatorAfter the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
Receives: Drug: S-ketamine (high-dose)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mechanical hyperalgesia threshold on the palms of feet

    The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament.

    Measured: 48 hours after surgery

Secondary outcomes (7)
  1. Pain Score (NRS)

    The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0 = no pain, 10 = greatest imaginable pain.

    Measured: 48 hours after surgery

  2. Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm

    The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament

    Measured: 48 hours after surgery

  3. Time of First Postoperative Analgesic Requirement

    First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.

    Measured: 1 hour after surgery

  4. Total Dose of First Postoperative Analgesic Requirement

    First postoperative pain (NRS≥5) is initially controlled by titration of sufentanyl.

    Measured: 1 hour after surgery

  5. Cumulative Sufentanyl Consumption

    Each patient was administered analgesics using a PCA (Patient-controlled analgesia) pump containing sufentanil (100μg) in normal saline at a total volume of 100 ml after leaving PACU (Postanesthesia care unit). This device was set to deliver a basal infusion of 2 ml/h and bolus doses of 0.5 ml with a 15-min lockout period. Sufentanyl cumulative consumption is recorded 48 hours postoperatively

    Measured: 48 hours after surgery

  6. Occurrence of Side Effects

    Occurrence of side effects: nausea, vomiting, dizziness, headache, shivering, pruritus

    Measured: 48 hours after surgery

  7. Mini-Mental State Examination (MMSE)

    Cognitive performance was assessed with Mini-Mental State Examination (MMSE).

    Measured: 48 hours after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2020
  2. Study start15 Dec 2020
  3. Primary completion15 Nov 2021 (estimated)
  4. Study completion15 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04643132
Sponsor's protocol ID
GWang011
Status last verified
Aug 2021
First submitted
17 Nov 2020
Last updated
13 Aug 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Zhang L, Terrando N, Xu ZZ, Bang S, Jordt SE, Maixner W, Serhan CN, Ji RR. Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. Front Pharmacol. 2018 May 1;9:412. doi: 10.3389/fphar.2018.00412. eCollection 2018.

    PubMed 29765320
  • Cui W, Li Y, Wang Z, Song C, Yu Y, Wang G, Li J, Wang C, Zhang L. Spinal caspase-6 regulates AMPA receptor trafficking and dendritic spine plasticity through netrin-1 in postoperative pain after orthopedic surgery for tibial fracture in mice. Pain. 2021 Jan;162(1):124-134. doi: 10.1097/j.pain.0000000000002021.

    PubMed 32701657

Questions about this trial

What is this clinical trial studying?

A study testing Normal saline, S-ketamine (low-dose) and S-ketamine (high-dose) in people with Postoperative Pain and Postoperative Cognitive Dysfunction, run by Tianjin Medical University General Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Guolin Wang, MD (+8615822855556, wangguolinghad@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mechanical hyperalgesia threshold on the palms of feet (time frame: 48 hours after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04643132, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2021; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in